Last reviewed · How we verify
Efficacy of Botox subdermally at Week 30 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Efficacy of Botox subdermally at Week 30 (Efficacy of Botox subdermally at Week 30) — ASIS Corporation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Efficacy of Botox subdermally at Week 30 TARGET | Efficacy of Botox subdermally at Week 30 | ASIS Corporation | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Efficacy of Botox subdermally at Week 30 CI watch — RSS
- Efficacy of Botox subdermally at Week 30 CI watch — Atom
- Efficacy of Botox subdermally at Week 30 CI watch — JSON
- Efficacy of Botox subdermally at Week 30 alone — RSS
Cite this brief
Drug Landscape (2026). Efficacy of Botox subdermally at Week 30 — Competitive Intelligence Brief. https://druglandscape.com/ci/efficacy-of-botox-subdermally-at-week-30. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab